Sanyou signs two commercial-use licenses for Horizon’s gene-edited CHO-K1 GS knockout cell line, for use in biotherapeutic pipeline development and contract research services
You Might Also Like
Twist Bioscience Launches Synthetic RNA Positive Controls for SARS-CoV-2 Encapsulated in Imagene’s Stainless Steel Capsules
Codex DNA Expands End-to-End Automated Synthetic Biology Workstation Enabling High Throughput Synthesis from DNA Sequence to Biologically Active mRNA
